David W. Gibbs has filed a Form 3 with the SEC, revealing his ownership of shares in Amgen Inc. This filing is significant as it reflects compliance with SEC regulations concerning insider ownership disclosures.

Background

Gibbs David W is associated with Amgen Inc, a prominent company in the biological products sector. The company, identified by CIK 0000318154, is listed under the SIC classification for Biological Products (No Diagnostic Substances) [2836]. Amgen is incorporated in Delaware and has its fiscal year ending on December 31.

What the Filing Says

The filing, dated October 27, 2026, indicates that Gibbs owns one security in Amgen. The report was filed as of October 26, 2026, and is part of ongoing disclosures required by the SEC.

Impact

This filing may affect stakeholders in Amgen, including investors and analysts who track insider ownership as a measure of confidence in the company's future. Gibbs serves as a director, which adds weight to the disclosure of his ownership.

What's Next

The filing does not say what happens next.

Ownership Details

According to the filing, David W. Gibbs owns one security in Amgen Inc. The specific security type is not detailed in the filing, but it is noted that Gibbs is a director of the company, which typically implies a significant role in corporate governance.

Power of Attorney

The filing also includes a Power of Attorney, which designates Andrea A. Robinson and Dennis Yai as Gibbs' attorneys-in-fact. This allows them to execute Forms 3, 4, and 5 on his behalf, ensuring compliance with SEC regulations regarding insider transactions. The Power of Attorney remains effective until Gibbs is no longer required to file these forms or until it is revoked in writing.

Contact Information

The filing lists Gibbs' mailing address as 7100 Corporate Drive, Plano, TX 75024, while his business address is provided as One Amgen Center Drive, Thousand Oaks, CA 91320. This information may be relevant for stakeholders seeking to contact him directly.

Additional Information

The filing does not include details about the nature of the security owned by Gibbs, such as whether it is a stock option, restricted stock, or another type of equity. Furthermore, it does not provide insights into any future plans regarding his ownership or potential transactions involving Amgen securities.